论文部分内容阅读
目的:评价膀胱肿瘤复发及进展评分对非肌层浸润性膀胱肿瘤预后判断的价值。方法:收集自2006年7月～2010年3月于我院接受腔内治疗的248例T_a和T_1期膀胱肿瘤患者临床资料,记录肿瘤数量、肿瘤大小、肿瘤临床分期、病理级别、既往有无肿瘤复发及有无伴随原位癌等相关资料,以EORTC(The EuropeanOrganization for Research and Treatment of Cancer)肿瘤风险评分表对患者评分,随访术后患者肿瘤复发及进展情况。结果:本组肿瘤复发危险评分为0～15分,平均(4.37±2.93)分;肿瘤进展危险得分为0～23分,平均(5.21±3.95)分。随访3～60个月,平均(25.8±18.5)个月,共有123例(49.6%)肿瘤复发,平均(11.4±6.5)个月。87例(70.7%)于1年内肿瘤复发,36例(29.3%)复发超过1年。24例(19.5%)肿瘤进展(平均(9.8±6.2)个月)。复发评分0～2分者肿瘤复发不足20%,进展评分0～2分者肿瘤无进展,3分者肿瘤进展率为6.1%。肿瘤数量是肿瘤复发与进展的首要危险因素,相对危险度分别为2.229和5.246。结论:肿瘤复发及进展评分可简便准确地判断非肌层浸润性膀胱肿瘤患者预后,但仍有修改与完善的必要。
Objective: To evaluate the value of bladder cancer recurrence and progression score in predicting the prognosis of non-muscle invasive bladder tumor. Methods: The clinical data of 248 T-a and T-1 bladder cancer patients who received endovascular treatment in our hospital from July 2006 to March 2010 were collected. The number of tumor, tumor size, clinical stage, pathological grade, Tumor recurrence and with or without accompanying cancer in situ. The patients were scored according to the EORTC (The European Organization for Research and Treatment of Cancer) tumor risk score, and the patients were followed up for tumor recurrence and progression. Results: The risk of tumor recurrence in this group was 0-15 points (average 4.37 ± 2.93). The risk score of tumor progression was 0-23 points (mean 5.21 ± 3.95). All patients were followed up for 3 to 60 months (mean, 25.8 ± 18.5 months). A total of 123 patients (49.6%) had tumor recurrence with an average of (11.4 ± 6.5) months. Tumor recurrence occurred in 87 (70.7%) patients within 1 year and in 36 (29.3%) patients for more than 1 year. 24 (19.5%) tumors progressed (mean (9.8 ± 6.2) months). Recurrence score 0 to 2 points less than 20% of tumor recurrence, progress score 0 to 2 points no progress of the tumor, 3 points, the rate of tumor progression was 6.1%. The number of tumors is the primary risk factor for tumor recurrence and progression with relative risk of 2.229 and 5.246, respectively. Conclusion: The tumor recurrence and progress score can be easily and accurately determine the prognosis of non-muscle invasive bladder cancer patients, but there is still the need for revision and improvement.